181 related articles for article (PubMed ID: 35640238)
1. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.
Chiodin G; Drennan S; Martino EA; Ondrisova L; Henderson I; Del Rio L; Tracy I; D'Avola A; Parker H; Bonfiglio S; Scarfò L; Sutton LA; Strefford JC; Forster J; Brake O; Potter KN; Sale B; Lanham S; Mraz M; Ghia P; Stevenson FK; Forconi F
Blood Adv; 2022 Sep; 6(18):5494-5504. PubMed ID: 35640238
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.
Drennan S; Chiodin G; D'Avola A; Tracy I; Johnson PW; Trentin L; Steele AJ; Packham G; Stevenson FK; Forconi F
Clin Cancer Res; 2019 Apr; 25(8):2503-2512. PubMed ID: 30373751
[TBL] [Abstract][Full Text] [Related]
3. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function.
Coelho V; Krysov S; Steele A; Sanchez Hidalgo M; Johnson PW; Chana PS; Packham G; Stevenson FK; Forconi F
Blood; 2013 Oct; 122(15):2664-72. PubMed ID: 23954894
[TBL] [Abstract][Full Text] [Related]
4. IL-4 enhances expression and function of surface IgM in CLL cells.
Aguilar-Hernandez MM; Blunt MD; Dobson R; Yeomans A; Thirdborough S; Larrayoz M; Smith LD; Linley A; Strefford JC; Davies A; Johnson PM; Savelyeva N; Cragg MS; Forconi F; Packham G; Stevenson FK; Steele AJ
Blood; 2016 Jun; 127(24):3015-25. PubMed ID: 27002119
[TBL] [Abstract][Full Text] [Related]
5. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
6. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.
Mockridge CI; Potter KN; Wheatley I; Neville LA; Packham G; Stevenson FK
Blood; 2007 May; 109(10):4424-31. PubMed ID: 17255355
[TBL] [Abstract][Full Text] [Related]
7. Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia.
Forconi F; Lanham SA; Chiodin G
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158929
[TBL] [Abstract][Full Text] [Related]
8. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL.
D'Avola A; Drennan S; Tracy I; Henderson I; Chiecchio L; Larrayoz M; Rose-Zerilli M; Strefford J; Plass C; Johnson PW; Steele AJ; Packham G; Stevenson FK; Oakes CC; Forconi F
Blood; 2016 Aug; 128(6):816-26. PubMed ID: 27301861
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
10. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
11. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
12. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
13. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
Front Immunol; 2020; 11():2158. PubMed ID: 32983178
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
Lama TG; Kyung D; O'Brien S
Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
[TBL] [Abstract][Full Text] [Related]
15. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
[No Abstract] [Full Text] [Related]
16. Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
Huang Q; Deering KL; Harshaw Q; Leslie LA
Adv Ther; 2022 Jul; 39(7):3292-3307. PubMed ID: 35608754
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia.
Rey-Barroso J; Munaretto A; Rouquié N; Mougel A; Chassan M; Gadat S; Dewingle O; Poincloux R; Cadot S; Ysebaert L; Quillet-Mary A; Dupré L
Haematologica; 2024 Mar; 109(3):809-823. PubMed ID: 37381758
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Chen TL; Harrington B; Truxall J; Wasmuth R; Prouty A; Sloan S; Lehman AM; Sampath D; Orlemans E; Baiocchi RA; Alinari L; Byrd JC; Woyach JA; Hertlein E
J Hematol Oncol; 2021 Feb; 14(1):36. PubMed ID: 33627156
[TBL] [Abstract][Full Text] [Related]
19. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
